AU609819C - Creación de Inventos y Patentes con Inteligencia Artificial

AU609819C – Methods for stimulating hair growth
– Google Patents

AU609819C – Methods for stimulating hair growth
– Google Patents
Methods for stimulating hair growth

Info

Publication number
AU609819C

AU609819C
AU17296/88A
AU1729688A
AU609819C
AU 609819 C
AU609819 C
AU 609819C
AU 17296/88 A
AU17296/88 A
AU 17296/88A
AU 1729688 A
AU1729688 A
AU 1729688A
AU 609819 C
AU609819 C
AU 609819C
Authority
AU
Australia
Prior art keywords
carbon atoms
moieties containing
phenylalanyl
valyl
valine
Prior art date
1987-05-11
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Ceased

Application number
AU17296/88A
Other versions

AU609819B2
(en

AU1729688A
(en

Inventor
Loren Ralph Pickart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Procyte Corp

Original Assignee
Procyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1987-05-11
Filing date
1988-05-11
Publication date
1992-04-09

1988-05-11
Application filed by Procyte Corp
filed
Critical
Procyte Corp

1988-12-06
Publication of AU1729688A
publication
Critical
patent/AU1729688A/en

1991-05-09
Publication of AU609819B2
publication
Critical
patent/AU609819B2/en

1992-04-09
Application granted
granted
Critical

1992-04-09
Publication of AU609819C
publication
Critical
patent/AU609819C/en

2008-05-11
Anticipated expiration
legal-status
Critical

Status
Ceased
legal-status
Critical
Current

Links

Espacenet

Global Dossier

Discuss

Description

METHODS FOR STIMULATING HAIR GROWTH
Technical Field
The present invention relates to cosmetic compositions and the stimulation of hair growth in general, and more specifically, to the use of derivatives of glycyl-L- histidyl-L-lysine: copper(II) (GHL-Cu) as cosmetic compositions and in the stimulation of hair growth in warm-blooded animals.
Background Art
While attempts to grow hair date back approximately 5,000 years to ancient Egyptian formulas, and while in developed countries, approximately 50-100 million persons suffer from cosmetic hair loss, there has been relatively little significant progress in generating compositions and methods for stimulating the growth of hair. For instance, selected «hair growth» preparations which have been proposed include compositions of vitamins E, B2, and B6, crude drug extracts, karotin-solubilizing agents, germacides, and scalp-stimulating agents, all alleged to stimulate the growth of hair.
Another traditional treatment for the loss of hair has been hair transplantation. Briefly, plugs of skin containing hair are transplanted from areas of the scalp where the hair was growing to bald areas. This procedure is a costly one in addition to being time-consuming and relatively painful. Other non-drug approaches include ultra-violet radiation and exercise therapy.
Traditionally, one of the most common approaches to stimulating hair growth has been in the area of drug therapy. However, the use of drugs in this regard has met with limited success. One of the most promising composi

tions for stimulating the growth of hair is disclosed by Upjohn in U.S. Patent No. 4,596,812, which describes the use of a substance known as «Minoxidil.» However, while the results generated through the use of Minoxidil have heretofore appeared promising, there is still a need in the art for improved compositions capable of stimulating the growth of hair in warm-blooded animals. The present invention fulfills this need, while further providing other related advantages.
Disclosure of the Invention
Briefly stated, the present invention discloses pharmaceutical and cosmetic compositions for use, in part, within a method for stimulating the growth of hair in warm-blooded animals. The method generally comprises administering to the animal a stimulatory amount of a derivative of GHL-Cu having the general formulas

wherein R is selected from the group consisting of alkyl moieties containing from one to eighteen carbon atoms, aryl moieties containing from six to twelve carbon atoms, alkoxy moieties containing from one to twelve carbon atoms, and aryloxy moieties containing from six to twelve carbon atoms, or where R is L-prolyl-L-valyl-L-phenylalanyl-L-valine or L-valyl-L-phenylalanyl-L-valine.
In addition to the derivatives described above, other chemical modifications could be made to alter the biological activity of the derivatives of the present invention. For instance, glycine may be replaced by a variety of other small amino acids, including alanine, serine and valine. Further, the copper (II) binding affinity of the molecule could be increased by addition of an N-terminal amino acid such as glycine to convert glycyl-L-histidyl-L-lysine to glycyl-L-glycyl-L-histidyl-L-lysine. In addition, glycine cou.ld be added to a derivative as described above to create the corresponding tetrapeptide.
The compositions described herein may be injected intradermally or applied topically, and are rendered suitable for administration to warm-blooded animals for the purposes of the present invention by combining the deriva

tive with a vehicle which adapts the composition for either intradermal injection or topical application to a warmblooded animal. Suitable vehicles include physiological saline. Other aspects of the present invention will become evident upon reference to the following detailed description and attached drawings.
Brief Description of the Drawings Figures 1 and 2 are photographs illustrating the stimulation of hair growth through the use of a representative derivative of the present invention.
Figure 3 is a microphotograph of a biopsy section taken through an area of enhanced hair growth. The photograph illustrates an increase in the density of hair follicles embedded in a heavy field of large, subcutaneous fat cells, as shown toward the right side of the figure.
Figure 4A is a photograph illustrating the stimulation of hair growth through the use of another representative derivative of the present invention.
Figure 4B is a microphotograph of a biopsy section taken through an area of enhanced hair growth, generated by the derivative of Figure 4A. The photograph illustrates an increase in the density of hair follicles within the subcutaneous fat cell layer in the area near the injection site.
Figure 5 is a microphotograph of a control area (bottom) and an area of increased subcutaneous fat cells and hair follicle density (top) generated through use of a representative derivative of the present invention.
Figure 6 is a photograph illustrating the stimulation of hair growth around a surgical defect utilizing a derivative of the present invention.
Figure 7 is a photograph illustrating enhanced hair growth surrounding a healing wound in a horse.

Best Mode for Carrying Out the Invention
As described herein, various derivatives of GHL-Cu may be used to stimulate the growth of hair in warmblooded animals. In addition, these derivatives can be tailored to increase their fat solubility, resulting in a form of the molecule which is more useful in a formulation of pharmaceutical and cosmetic creams and gels. The derivatives of the present invention are described in detail in pending U.S. Patent Application No. 040,460 and U.S. Patent No. 4,665,054, which documents are hereby incorporated by reference. The derivatives of the present invention may be prepared by esterification, by the removal of a water molecule, or by the addition of a group (either an alcohol such as octanol, methanol, benzol alcohol or NH3) to the carboxylic acid terminus of GHL, resulting in the formation of the more lipophilic derivative. This increases fat solubility by (1) removal of the electric charge associated with the carboxylic acid group and (2) the introduction of hydrophilic groups into the molecule.
The overall chemical reaction in this transformation may be characterized as:
GHL – OH + R – H —> GHL – R + H2O.
In practice, the reaction is most readily carried out by adding the R group to the amino acid lysine prior to the combination of lysine with the other two amino acids to GHL. After the formation and isolation of GHL-R, the copper (II) is chelated to the molecule to form the bioactive complex. The overall reaction to form the more lipophilic derivatives of GHL-Cu may be characterized:
1) lysine-OH + R-H —–> lysine-R + H2O
2) lysine-R + blocked L-histidine —–> blocked
L-histidine-L-lysine-R 3) blocked L-histidine-L-lysine-R + blocked-glycine —–> blocked glycyl-L-histidine-L-lysine-R

4) blocked glycyl-L-histidine-L-lysine-R —–> glycyl-L-histidine-L-lysine-R
5) glycyl-L-histidine-L-lysine-R + copper (II) —–> glycyl-L-histidine-L-lysine-Rs copper (II). Within preferred embodiments, the derivative of
GHL and copper are present in a 1:1 or 2:1 ratio.
As noted above, the derivatives of the present invention are useful in stimulating the growth of hair in warm-blooded animals. While one of the characteristics associated with male pattern baldness is the severe diminution of hair follicles, use of the derivatives as described herein results in increased adipocyte formation, which is spatially and temporally linked with hair follicle formation, and is an integral phase of hair follicle formation (Hausman- et al., Am. J. Anat. 161: 85-100, 1981). The results of the use of the derivatives as described herein are illustrated, in part, in Figures 3, 4B and 5, which, are microphotographs of areas of enhanced hair growth.
The enhancement of subcutaneous fat in areas associated with increased hair growth is highly significant. Male pattern baldness is intimately associated with a dramatic reduction in the amount of subcutaneous fat associated with hair follicles that are nonproductive. Conversely, during periods of rapid hair growth in mammals, the subcutaneous fat content increase two- to threefold.
The derivatives of the present invention have clinical use in at least four primary areas: (1) the direct stimulation of hair growth in persons with hair loss, (2) the stimulation of hair transplants, (3) increasing the subcutaneous fat content, and (4) in general cosmetic applications.
Within the present invention, it is generally preferred to administer the derivatives described herein intradermally in the center of the area to be treated, along with a suitable vehicle in a concentration of approximately 50 micrograms of derivative per .1 ml of vehicle. It is preferable to use a dosage of approximately 9 micro

grams per cm2 of area to be treated, although dosages greater than 9 micrograms/cm2, up to approximately 40 micrograms/cm2, may be used. Suitable vehicles in this regard include saline. When used in the form of a cream or gel and applied topically, it is useful to add a suitable penetrating agent, such as DMSO, to the composition. Suitable vehicles for use in cosmetic applications will be evident to those skilled in the art. For cosmetic purposes, the composition may further contain a moistening agent, softening agent, perfume or colorant.
To summarize the examples which follow, Example I illustrates the synthesis of glycyl-L-histidyl-L-lysine benzyl ester: copper(II). Example II demonstrates the syunthesis of glycyl-L-histidyl-L-lysine n-octyl ester: copper(II). Example III illustrates (A) the synthesis of glycyl-L-histidyl-L-lysine n-stearyl ester: copper(II), and (B) its synthesis by an alternative procedure. Based upon either procedure, one skilled in the art could substitute n-palmityl alcohol (16 carbons), for the n-stearyl alcohol (18 carbons) to yield glycyl-L-histidyl-L-lysine n-stearyl ester: copper(II). Example IV illustrates the synthesis of glycyl-L-histidyl-L-lysyl-L-prolyl-L-valyl-L-phenylalanyl-L-valine: copper (II) and glycyl-L-histidyl-L-lysyl-L-valyl-L-phenylalanyl-L-valine: copper (II). Examples V, VI and VII illustrate the hair growth stimulating activity of preferred derivatives of the present invention. Example VIII demonstrates the stimulation of hair growth around healing wounds in warm-blooded animals.
The following examples are offered by way of illustration and not by way of limitation.
EXAMPLES
Sources of chemicals. Chemicals and peptide intermediates utilized in the following examples may be purchased from the following suppliers: Sigma Chemical Co.
(St. Louis, Mo.); Peninsula Laboratories (San Carlos,

Calif.); Aldridge Chemical Co. (Milwaukee, Wis.); Vega Biochemicals (Tucson, Ariz.); Pierce Chemical Co. (Rockford, Ill.); Research Biochemicals (Cleveland, Ohio); Van Waters and Rogers (South San Francisco, Calif.); Bachem, Inc. (Torrance, Calif.).
EXAMPLE I Synthesis of glycyl-L-histidyl-L-lysine benzyl ester: copper (II) Ne-benzyloxycarbonyl-L-lysine benzyl ester was dissolved in 1:1 hexane-ethyl acetate and coupled to Na-t-butyloxycarbonyl-Nim-benzyloxycarbonyl-L-histidine using dicyclohexylcarbodiimide as a coupling agent. Sodium bicarbonate (10%) was added and the product extracted into the organic layer. The product, Na-t-butyloxycarbonyl-Nim-benzyloxycarbonyl-L-histidyl-Ne-benzyloxycarbony1-L-lysine benzyl ester, was crystallized from solution. The N-terminal group of the blocked dipeptide was removed by stirring in 50% trifluoroacetic acid in dichloromethane for 30 minutes, then vacuum evaporated. The product, Nim-benzyloxycarbony1-L-histidyl-Ne-benzoylcarbony1-L-lysine benzyl ester, was coupled to benzyloxycarbonylglycine with dicyclohexylcarbodiimide as a coupling agent. Blocking groups were removed by catalytic hydrogenation using 10% palladium on carbon in glacial acetic acid. After lyophilization, the product, glycyl-L-histidyl-L-lysine benzyl ester, was dissolved in water and purified by ion-exchange chromatography on Dowex 50 X-4 cation-exchange resin and elution with 0.1 M ammonium hydroxide, the eluate being immediately neutralized with acetic acid. A further passage through an anion-exchange column BioRex 63 at neutral pH removed breakdown products with free carboxylic acid groups.
The glycyl-L-histidyl-L-lysine benzyl ester was dissolved in water with equimolar copper acetate added. The pH was raised to neutrality with sodium hydroxide. The solution was centrifuged at 20,000 × g for 1 hour at 3°C to

remove poorly water-soluble material. The supernatant was lyophilized to obtain glycyl-L-histidyl-L-lysine benzyl ester: copper (II).
EXAMPLE II
Synthesis of glycyl-L-histidyl-L-lysine n-octyl ester: copper (II)
A mixture of Ne-benzyloxycarbonyl-L-lysine, n-octanol, benzene, and p-toluenesulfonic acid monohydrate was refluxed overnight using a Dean-Stark trap to remove water. After cooling, dry ethyl ether was added. The solution was then allowed to precipitate at 0°C overnight. A portion of the precipitated solid was added to 50 ml potassium carbonate solution and 50 ml dichloromethane. After extraction, the layers were separated and the organic phase washed with water and brine, then dried with anhydrous magnesium sulfate. Filtration, evaporation and purification by flash column chromatography gave n-octyl Ne-benzyloxycarbonyl-L-lysinate. The product was dissolved in tetrahydrofuran and mixed with Na-t-butyloxycarbonyl-L- Nim-benzyloxycarbonyl-L-histidine, isobutyl chloroformate and N-methylmorpholine. After evaporation, water and ethyl acetate were added. The product was extracted into the organic phase, which was dried with anhydrous magnesium sulfate. Filtration, evaporation and purification by flash column chromatography gave n-octyl Na-t-butyloxycarbonylNim-benzyloxycarbony1-L-histidyl-Ne-benzyloxycarbony1-L-lysinate.
The product was dissolved in 50% trifluoroacetic acid in dichloromethane for 30 minutes, then evaporated, forming n-octyl Nim-benzyloxycarbonyl-L-histidyl-Ne-benzyloxycarbonyl-L-lysinate. This was dissolved in tetrahydrofuran, and isobutyl chloroformate, N-methylmorpholine and benzyloxycarbonylglycine were added to form n-octyl benzyloxycarbonylglycyl-Nim-benzyloxycarbony1-L-histidyl-Ne-benzyloxycarbonyl-L-lysinate. This was dissolved in glacial acetic acid and hydrogenated overnight.

The resultant n-octyl ester of glycyl-L-histidyl-L-lysine was converted to the copper-complex by the addition of an equimolar quantity of copper diacetate. The pH was raised to neutrality with sodium hydroxide. The solution was centrifuged at 20,000 x g for 1 hour at 3°C to remove poorly water-soluble material. The supernatant was lyophilized to obtain glycyl-L-histidyl-L-lysine n-octyl ester: copper (II).
EXAMPLE III
A. Synthesis of glycyl-L-histidyl-L-lysine n-stearyl esters copper (II)
A mixture of Ne-benzyloxycarbonyl-L-lysine, n-stearyl alcohol, benzene, and p-toluenesulfonic acid monohydrate was refluxed overnight using a Dean-Stark trap to remove water. After cooling, dry propyl ether was added to increase the total volume sixfold. The product was allowed to precipitate at 0°C overnight and filtered. A portion of the filtrate was added to 50 ml potassium carbonate and 50 ml dichloromethane. After extraction, the layers were separated, and the organic phase was washed with water and brine, then dried with anhydrous magnesium sulfate. Filtration, evaporation and purification by flash column chromatography gave n-stearyl Ne-benzyloxycarbonyl-L-lysinate. The product was dissolved in tetrahydrofuran and mixed with Na-t-butyloxycarbonyl-Nim-benzyloxycarbonyl-L-histidine and isobutyl chloroformate and N-methylmorpholine. After evaporation, water and propyl acetate were added and the product was extracted into the organic phase, then dried with anhydrous magnesium sulfate. Filtration, evaporation and purification by flash column chromatography gave n-stearyl Na-t-butyloxycarbσnyl-Nim-benzyloxycarbonyl-L-histidyl-Ne-benzyloxycarbonyl-L-lysinate.
The product was dissolved in 50% trifluoroacetic acid in dichloromethane for 30 minutes, then evaporated, forming n-stearyl Nim-benzyloxycarbonyl-L-histidyl-Ne-benzyloxycarbonyl-L-lysinate, which was dissolved in

tetrahydrofuran, isobutyl chloroformate, N-methylmorpholine and benzyloxycarbonylglycine to form n-stearyl benzyloxycarbonylglycyl-Nim-benzyloxycarbonyl-L-histidyl-Ne-benzyloxycarbonyl-L-lysinate. The product was dissolved in 50% trifluoroacetic acid in dichloromethane for 30 minutes, then evaporated, forming n-stearyl ester glycyl-L-histidyl- L-lysine.
The resultant molecule, glycyl-L-histidyl-L-lysine n-stearyl ester, was converted to the copper complex by the addition of an equimolar quantity of copper diacetate. The pH was raised to neutrality with sodium hydroxide to obtain a product useful for animal studies.
By substituting n-palmityl alcohol for the n-stearyl alcohol, glycyl-L-histidyl-L-lysine n-palmityl ester may be similarly synthesized.
B. Alternative synthesis of glycyl-L-histidy]-L-lysine n-stearyl ester: copper (II)
N(ε)-benzyloxycarbonyl-L-lysine, n-stearyl alcohol, p-toluenesulfonic acid monohydrate, and benzene are refluxed together using a Dean-Stark trap to azeotropically remove the evolved water. After cooling to room temperature and then adding dry ethyl ether, n-stearyl N(ε)-benzyloxycarbonyl-L-lysinate p-toluenesulfonate salt is collected by filtration, treated with 2 M aqueous potassium bicarbonate solution, and extracted into dichloromethane. Evaporation gives the free amine, which is redissolved in dry tetrahydrofuran (THF) and added to a stirring solution of N(α)-t-butyloxycarbonyl-N(im)-benzyloxy-carbonyl-L-histidine, N-methylmorpholine, and isobutyl chloroformate in dry THF at -15°C. The resulting fully protected dipeptide ester is treated with 1/1 trifluoroacetic acid/dichloromethane at room temperature, neutralized with saturated aqueous sodium bicarbonate solution, and extracted into ethyl acetate. Evaporation gives the partially deblocked dipeptide, which is redissolved in dry THF and added to a stirring solution of benzyloxycarbonyl

glycine, N-methylmorpholine and isobutyl chloroformate in dry THF at -15°C. The formed, fully protected tripeptide fester is totally deblocked by treatment with hydrogen gas in glacial acetic acid at room temperature in the presence of Pd-C catalyst. Filtration, evaporation and purification on a microcrystalline cellulose column followed by lyophilization give the desired tripeptide ester as its triacetate salt.
The resultant molecule, glycyl-L-histidyl-L-lysine n-stearyl ester, was converted to the copper-complex by the addition of an equimolar quantity of copper diacetate. The pH was raised to neutrality with sodium hydroxide to obtain a product useful for animal studies.
By substituting n-palmityl alcohol for the n-stearyl alcohol, glycyl-L-histidyl-L-lysine n-palmityl ester may be similarly synthesized.
EXAMPLE IV Synthesis of qlycy1-L-histidyl-L-lysyl-L-prolyl-L-valyl-L- phenylalanyl-L-valines copper (II) and of glycyl-L-histidyl- L-lysyl-L-valyl-L-phenylalanyl-L-valine: copper ( II)
These peptides are synthesized by standard solid- phase methods common to the peptide field (J. Stewart and J. Young, Solid Phase Peptide Synthesis, Pierce Chemical Co., 1984). Briefly stated, Boc-Val-O-Resin was sequentially coupled with other blocked amino acids using dicyclohexylcarbodiimide as a reaction agent. Protected amino acids, resins for solid-phase synthesis, and coupling agents were obtained from Peninsula Laboratories, San Carlos, California. Blocked amino acids are added in sequential order to obtain the desired peptide. The final peptide is deblocked using hydrogen fluoride. The final peptide is dissolved in 0.5% acetic acid and purified by passage through a Sephadex G-15 column (Pharmacia). Addition of equimolar cupric acetate, followed by lyophilization, produces the active molecule.

EXAMPLE V Use of glycyl-L-histidyl-L-lysine n-octyl ester: copper (II) to stimulate hair growth
A. Stimulation of hair growth in normal skin In order to demonstrate the stimulation of hair growth in warm-blooded animals, the backs of mice were shaved on day 1 using an electric shaver. Subsequently, a single dose of 50 micrograms of glycyl-L-histidyl-L-lysine n-octyl ester: Cu(II) was infiltrated under the skin in eight mice. As shown in Figure 1, by day 7 there was a markedly accelerated growth of hair around the injection area in all of the mice.
In some regions of enhanced hair growth, increased follicle densities were observed, along with increased amounts of subcutaneous fat.
In another series of experiments, mice were shaved and injected once with Glycyl-L-Histidyl-L-Lysine Octyl Ester :Copper (II) at a dose of 500 micrograms per mouse. Figure 2 shows that there was a significant acceleration of hair growth within 2-3 weeks following the injection. Mice injected with saline did not show an acceleration.
In the region of accelerated hair growth, there was a significant increase in the thickness of the subcutaneous fat layer. It is known that the thickness of this fat layer is directly associated with hair growth.
This increase in subcutaneous fat is shown by taking a biopsy sample at day 21 through the area and sectioning for histology slides. Figure 3 shows this increase in the fat layer. The injected area is on the right with the adjacent uninjected area on the left of the photograph. There was an increase in both the number and si.ze of the fat cells.
Measurements demonstrate that there was an approximately three-fold increase in the subcutaneous fat layer in the skin near the injection site.
These examples demonstrate that the stimulation of hair growth is observed both in normal skin and in newly

healing regions utilizing the derivatives of the present invention.
EXAMPLE VI Use of Glycyl-L-Histidyl-L-Lysine Decyl Ester Copper (II) to Stimulate Hair Growth in Mice
A group of ten mice were shaved and injected once with Glycyl-L-Histidyl-L-Lysine Decyl Ester : Copper (II) at a dose of 500 micrograms per mouse. Figure 4A shows that there was a significant acceleration of hair growth within
2-3 weeks following the injection. Microscopic examination also provided evidence of increased hair growth, fat cell layer, and increased hair follicle density in the area surrounding the injection site. Figure 4B shows that there was a marked proliferation of hair shaft units which appeared within the subcutaneous fat layer of the area of accelerated hair growth. Examination of the skin distant from the injection site showed a normal histology.
EXAMPLE VII
Use of Glycyl-L-Histidyl-L-Lysine Palmityl Ester Copper (II) to Stimulate Hair Growth in Mice A group of ten mice were shaved and injected once with Glycyl-L-Histidyl-L-Lysine Palmityl Ester : Copper (II) at a dose of 500 micrograms per mouse. There was a significant acceleration of hair growth within 2-3 weeks following the injection. Histological sections through the area of accelerated hair growth were similar to those described in Example VI. This is shown in Figure 5. The photomicrograph demonstrates the large number of developing hair follicles within the subcutaneous fat layer, similar to that seen following the Glycyl-L-EIistidyl-L-Lysine Decyl Ester: Cu injection.

EXAMPLE VIII Stimulation of Hair Growth Around Healing Wounds
Re-establishment of hair growth is a normal part of healing. As shown in Figure 6, the compositions described herein may be used to stimulate the growth of hair around a surgical defect. In this model system, a 1.2 cm diameter full thickness defect was created on the backs of mice. Immediately following the surgery, the defect was treated with a solution containing Glycyl-L-Histidyl-L-Lysine Octyl Ester:Copper (II). The enhanced hair growth after healing was well advanced at 7 to 10 days and spread outward from the treated area (Figure 6). The maximal differential effect versus the control mice was observed approximately 22 days after treatment. Treatment of a healing wound with Glycyl-L- Histidyl-L-Lysine:Copper (II) also causes an acceleration of hair growth. A horse with a deep, ulcerating wound was treated with a topical cream containing 0.4% Glycyl-L-Histidyl-L-Lysine:Copper (II) to accelerate the healing process. As part of the treatment protocol, the hair surrounding the wound was clipped to aid in cleansing the area. Treatment with the cream occurred every day until the wound was closing, followed by less frequent application. After 5 weeks, the wound was almost totally healed with only a small residual scab. As shown in Figure 7, there was a significant acceleration of hair growth surrounding the treated area when compared with the untreated areas.
From the foregoing it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not to be limited except as by the appended claims.

Claims (11)

Claims

1. A composition comprising a derivative of GHL-Cu having the general formula:

wherein R is selected from the group consisting of alkyl moieties containing from 1 to 18 carbon atoms, aryl moieties containing from 6 to 12 carbon atoms, alkoxy moieties containing from 1 to 12 carbon atoms, and aryloxy moieties containing from 6 to 12 carbon atoms, or where R is L-prolyl-L-valyl-L- phenylalanyl-L-valine or L-valyl-L-phenylalanyl-L-valine, for use in stimulating the growth of hair in warm-blooded animals.

2. The composition of claim 1 wherein the alkyl moiety is an unbranched chain.

3. The composition of claim 2 wherein the unbranched chain is an n-octyl moiety.

4. The composition of claim 1 wherein the alkyl moiety is an n-stearyl moiety.

5. The composition of claim r wherein the alkyl moiety is an n-palmityl moiety.

6. The composition of claim 1 wherein the aryl moiety is a benzyl moiety.

7. The composition of claim 1 wherein said derivative is injected intradermally.

8. A pharmaceutical composition suitable for administration to warm-blooded animals for stimulating the growth of hair, comprising: a derivative of GHL-Cu having the general formula:

wherein R is selected from the group consisting of alkyl moieties containing from 1 to 18 carbon atoms, aryl moieties containing from 6 to 12 carbon atoms, alkoxy moieties containing from 1 to 12 carbon atoms, and aryloxy moieties containing from 6 to 12 carbon atoms, or where R is L-prolyl-L-valyl-L-phenylalanyl-L-valine or L-valyl-L-phenylalanyl-L-valine; and a vehicle which adapts said composition for intradermal injection or topical application to a warm-blooded animal.

9. A composition comprising a derivative of GHL-Cu having the general formula:

wherein R is selected from the group consisting of alkyl moieties containing from 1 to 18 carbon atoms, aryl moieties containing from 6 to 12 carbon atoms, alkoxy moieties containing from 1 to 12 carbon atoms, and aryloxy moieties containing from 6 to 12 carbon atoms, or where R is prolyl-L-valyl-L-phenylalanyl-L-valine or valyl-L-phenylalanyl-L-valine, for use in increasing subcutaneous fat in a warm-blooded animal.

10 o A composition comprising a derivative of GHL-Cu having the general formulas

wherein R is selected from the group consisting of alkyl moieties containing from 1 to 18 carbon atoms, aryl moieties containing from 6 to 12 carbon atoms, alkoxy moieties containing from 1 to 12 carbon atoms, and aryloxy moieties containing from 6 to 12 carbon atoms, or where R is L-prolyl-L-valyl-L-phenylalanyl-L-valine or L-valyl-L-phenylalanyl-L-valine, for use in increasing the density of hair follicles in warm-blooded animals.

11. A cosmetic composition comprising a derivative of GHL-Cu having the general formula:

wherein R is selected from the group consisting of alkyl moieties containing from 1 to 18 carbon atoms, aryl moieties containing from 6 to 12 carbon atoms, alkoxy moieties containing from 1 to 12 carbon atoms, and aryloxy moieties containing from 6 to 12 carbon atoms, or where R is L-prolyl-L-valyl-L- phenylalanyl-L-valine or L-valyl-L-phenylalanyl-L-valine, for use in increasing the density of hair follicles in warm-blooded animals.

AU17296/88A
1987-05-11
1988-05-11
Methods for stimulating hair growth

Ceased

AU609819C
(en)

Applications Claiming Priority (2)

Application Number
Priority Date
Filing Date
Title

US4844487A

1987-05-11
1987-05-11

US048444

1987-05-11

Publications (3)

Publication Number
Publication Date

AU1729688A

AU1729688A
(en)

1988-12-06

AU609819B2

AU609819B2
(en)

1991-05-09

AU609819C
true

AU609819C
(en)

1992-04-09

Family
ID=

Información de contacto